BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pathology News - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pathology News
X-ORIGINAL-URL:https://www.pathologynews.com
X-WR-CALDESC:Events for Pathology News
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20261025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20250916T130000
DTEND;TZID=Europe/London:20250916T140000
DTSTAMP:20260829T173433
CREATED:20250827T133756Z
LAST-MODIFIED:20250827T152729Z
UID:100115251-1758027600-1758031200@www.pathologynews.com
SUMMARY:Can AI Predict Patient Outcomes in Ovarian Cancer?
DESCRIPTION:0000Days00Hrs00Min00SecExperimental image-based AI models are very good at extracting new information from standard H&E pathology slides. However\, the biological interpretation of these novel findings is a challenge. In this webinar\, Dr. Anna Laury\, Clinical Researcher at the University of Helsinki\, will explain how they used scanned H&E slides of high-grade serous carcinoma of the tube/ovary (HGSC) together with spatially resolved transcriptomics to explore whether AI findings actually represent biological differences in these tumors. \nHigh-grade serous carcinoma of the tube/ovary (HGSC) is characterized by aggressive behavior\, chemotherapy resistance\, and low 5-year survival\, but also exhibits striking variability in outcome. Our understanding of this disease is limited\, partly due to considerable tumor heterogeneity\, and predicting any individual patient’s response to therapy is challenging. \nDr. Laury’s team used Aiforia® Create to train an AI model to predict patient outcome in HGSC by identifying tumor regions that are highly associated with outcome status. The tumor regions identified by the AI model are currently indistinguishable by pathologists. They then used spatially resolved transcriptomics to profile these AI-identified tumor regions and identify molecular features related to disease outcome. \nRegister for the webinar to hear more about this proof-of-concept study\, which shows that AI-guided spatial transcriptomic analysis improves recognition of biologic features relevant to patient outcomes. \nRegister NowSpeakersAnna Laury\, MD\, PhD\nClinical Researcher\nUniversity of Helsinki \nDr. Laury is a clinical researcher at the University of Helsinki. She received her medical degree from the University of California\, Los Angeles and pathology training at Brigham & Women’s Hospital. Her clinical interests include women’s and perinatal pathology\, and her research is currently focused on the development and progression of tubo-ovarian serous carcinoma. \nDarshan Kumar\, PhD\nDirector of the Global FAS team\nAiforia Technologies \nDarshan Kumar has worked at Aiforia for over four years as a Customer Success Manager and Scientist. He currently leads the global team of Field Application Scientists. He did his PhD research in cell and molecular biology at the University of Helsinki and has a master’s in Biomedical Sciences from Leiden University.
URL:https://www.pathologynews.com/event/can-ai-predict-patient-outcomes-in-ovarian-cancer/
LOCATION:Online
CATEGORIES:Live Online Webinar
ATTACH;FMTTYPE=image/jpeg:https://www.pathologynews.com/wp-content/uploads/2025/08/Can-AI-Predict-Patient-Outcomes-in-Ovarian-Cancer.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20250918T160000
DTEND;TZID=Europe/London:20250918T170000
DTSTAMP:20260829T173433
CREATED:20250827T150458Z
LAST-MODIFIED:20250827T152522Z
UID:100115270-1758211200-1758214800@www.pathologynews.com
SUMMARY:Intro to HALO®\, HALO AI\, and HALO Link 4.2
DESCRIPTION:0000Days00Hrs00Min00SecLearn about the exciting new features in the 4.2 versions of HALO\, HALO AI\, and HALO Link!\nSummaryIn this webinar\, Indica Labs will explore the new features and functionalities in HALO\, HALO AI\, and HALO Link 4.2 designed to enhance performance\, streamline workflows\, and expand analytical capabilities. In HALO 4.2\, new annotation tools such as a multi-select feature and improved annotation management\, including batch annotation import and rename\, boost efficiency. Also\, object data is moved out from the database into optimized parquet files\, significantly improving load times and overall system performance. \nHALO AI 4.2 offers channel-invariant pretrained models that streamline nuclear and cell segmentation by leveraging all fluorescent channels\, and multiple membrane markers can now be selected when further training the pretrained membrane segmentation model. Version 4.2 also brings an updated AI annotation tool that is smaller\, faster\, and optimized for pathology data\, delivering a smoother annotation experience. Users now have greater control over model training with adjustable hyperparameters\, including learning rates and class weights. \n\nIn version 4.2\, HALO Link now supports viewing Z-stacks on brightfield images. The latest version also introduces a Diagnostic Monitor add-on to help administrators troubleshoot performance issues with image loading. For those looking for additional ergonomics options\, integration with the 3D Connexion SpaceMouse is now available. Finally\, both HALO and HALO Link 4.2 support the use of third-party AI apps\, enabling models developed by users outside of HALO or by external vendors to be launched and viewed within the platforms. \n\nLearning Objectives\nLearn about third party AI Analysis support through API \nLearn about new annotation tools and object data storage in HALO \nLearn about streamlined nuclear and membrane segmentation using channel invariant pretrained models  \nLearn about using the 3D Connexion SpaceMouse for more ergonomic slide navigation in HALO Link \n\nRegister NowPresenterDr. Noemi Kedei\nDirector of Product\, Life Sciences\nIndica Labs  \nNoemi Kedei earned an MD degree from University Medical School of Debrecen\, Hungary. She did her postdoctoral training and worked later as a staff scientist in the Laboratory of Cancer Biology and Genetics\, NCI. Her research focused on identifying mechanisms involved in the differential effects of natural compounds and their engineered derivatives acting on protein kinase Cs (PKCs)\, validated targets for anti-cancer treatment. In 2018 she joined the Collaborative Protein Technology Resources (OSTR\, CCR\, NCI) core facility to implement a variety of spatial protein and transcriptomics technologies\, and lead related operations as services to NCI investigators. Noemi provided the expertise for development of project based customized antibody protein panels for detection of 40-60 protein targets at single cell level in tissue sections using the CODEX/Phenocycler fusion technology\, and ensured optimal and efficient instrument use. In addition\, she advised and supported users on tools for quantitative image analysis combining different AI-enabled HALO modules and NCI developed pipelines for downstream analysis. Noemi joined Indica Labs as Director of Product – Life Sciences in May\, 2025. 
URL:https://www.pathologynews.com/event/intro-to-halo-halo-ai-and-halo-link-4-2/
LOCATION:Online
CATEGORIES:Live Online Webinar
ATTACH;FMTTYPE=image/jpeg:https://www.pathologynews.com/wp-content/uploads/2025/08/Intro-to-HALO®-HALO-AI-and-HALO-Link-4.2.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20250929T140000
DTEND;TZID=Europe/London:20250929T150000
DTSTAMP:20260829T173433
CREATED:20250827T141747Z
LAST-MODIFIED:20250829T120221Z
UID:100115260-1759154400-1759158000@www.pathologynews.com
SUMMARY:Evaluation of HER2-Low and Ultralow Status of Advanced Breast Carcinomas
DESCRIPTION:0000Days00Hrs00Min00SecJoin this webinar to discover how digital pathology with AI evaluation is a more sensitive method for HER2-low assessment. Dr. Anikó Kovács (Department of Clinical Pathology\, Sahlgrenska University Hospital\, Gothenburg\, Sweden) will present findings from a retrospective study on the HER2-low status of advanced breast carcinomas in core biopsies. \nThe aim of the study was to: \n\ncompare the outcome of HER2 scoring using conventional microscopy\, digital pathology\, and AI.\nassess changes in HER2-low status in core biopsies\, matching operation specimens\, and their distant metastases.\n\nRegister for the webinar to learn more about the findings and how AI can help determine a more accurate HER2-low status\, providing an exact percentage of each HER2 score within seconds with high accuracy. \nWho should join?\n\nPathologists involved in biomarker testing\nOncologists relying on HER2-low status in treatment decisions\nAnyone involved in breast cancer diagnostics or therapeutic decision-making\nAnyone interested in using or developing AI models for image analysis in digital pathology\n\nRegister NowSpeakersAnikó Kovács\, MD\, PhD\nAssociate Professor\, Pathologist\, and Lecturer\nSahlgrenska University Hospital \n\nHas worked in research in Sweden for the past 23 years\nBreast cancer research at the Leicester University in the UK\nResearch background also in Japan (Kitasato University) and Hungary\n\nRute Pedrosa\, PhD\nSenior Field Application Scientist\nAiforia Technologies \n\nHas worked at Aiforia for 2.5 years\nPhD at Erasmus University Rotterdam\, focusing on the pathogenesis of brain metastatic disease
URL:https://www.pathologynews.com/event/evaluation-of-her2-low-and-ultralow-status-of-advanced-breast-carcinomas/
LOCATION:Online
CATEGORIES:Live Online Webinar
ATTACH;FMTTYPE=image/jpeg:https://www.pathologynews.com/wp-content/uploads/2025/08/aiforia-her2-low-webinar-pathologynews.jpg
END:VEVENT
END:VCALENDAR